抗 TIGIT 抗体市场：市场机会和临床试验趋势 (2024)

TIGIT 是一种免疫检查点抑製剂，最近成为通过调节其在体内活性发挥作用的药物的靶标。 TIGIT 已开发出拮抗剂和激动剂，其中前者占主导地位，主要用于各种类型的人类疾病。 TIGIT 抑製剂似乎遵循与免疫检查点抑製剂类似的趋势，这些抑製剂已针对各种癌症进行了广泛的测试，这表明这些新型抑製剂证明了类似抑製剂所证明的治疗成功性。目前正在进行多项临床前和临床试验，以评估这是否可以復制。 其中几种 TIGIT 抑製剂现已接近监管部门的批准，并被认为是开发针对 TIGIT 的药物的主要推动力。

近几十年来，免疫检查点蛋白因其作为治疗靶点的潜力而引起了人们的极大兴趣。 TIGIT 等检查点蛋白在调节免疫系统中发挥着重要作用，它们的激活和抑制可能对身体产生有益或致命的后果，具体取决于疾病的适应症，也可能导致负面结果。 近年来，研究人员发现了新的免疫检查点蛋白，其中包括十多年前发现的 TIGIT。 该蛋白具有三个配体：TIGIT具有三个配体，CD155、CD112和CD113，它们都是Nectin和NECL分子家族的成员。

TIGIT 已被证明可以下调消除癌细胞所需的 T 细胞和 NK 细胞的活性，在癌症免疫週期的许多方面充当屏障。 临床前研究表明，TIGIT 阻断可以预防多种实体癌和血液癌。 在病毒和细菌感染中也进行了类似的观察，其中免疫系统的激活（对于免疫介导的感染细胞清除至关重要）被 TIGIT 激活所阻止。

为了抑制人TIGIT的抑制活性，已经生产了AZD2936、PM1009、Domvanalimab和PM1021等单克隆抗体和双特异性抗体。 TIGIT 抑制正在作为单一药物或与抗 PD-1/PD-L1 单克隆抗体联合治疗晚期实体瘤患者进行临床研究。

另一方面，在自身免疫性疾病的研究中，TIGIT 与疾病活动相关。 一组科学家宣布开发出抗小鼠 TIGIT 激动剂单克隆抗体。 这种激动性TIGIT抗体用于实验性自身免疫性脑脊髓炎模型小鼠，据称通过作用于两种不同效果的细胞并抑制T细胞活化来改善疾病症状。我做到了。 因此，TIGIT诊断抗体具有减少自身免疫性疾病中T细胞失衡的能力，有望在自身免疫性疾病的治疗中特别有效。

目前，临床试验中用于治疗自身免疫性疾病的TIGIT抗体均无拮抗作用。 同样，临床试验中也没有用于治疗病毒或细菌感染的拮抗抗体。

全球领先的製药公司正在开发 TIGIT 靶向药物，包括百时美施贵宝、罗氏、阿斯利康、Bioteus、Arcus Biosciences、百济神州、康方生物和 Compugen。 这些公司与耶鲁大学、匹兹堡大学和 MD 安德森癌症中心等大学和医疗机构合作，推动候选药物通过临床试验。 其中一些候选药物目前正处于临床试验的最后阶段，预计将获得监管部门的批准。

目前，针对TIGIT的药物未来市场前景看好。 此外，TIGIT 激动剂和拮抗剂的治疗在癌症以外的适应症中显示出前景，并且广泛的抗 TIGIT 药物表明了疾病扩展的潜力。 首个TIGIT蛋白靶向药物预计将在未来几年内上市，引发一系列药物研发和商业化项目，加大投资力度，开发优化的抗TIGIT药物。使能够 此外，随着人工智能和纳米技术进入药物发现、开发和药物输送过程，拥有人工智能和纳米技术基础的公司预计将在 TIGIT 治疗行业中获得越来越突出和重要的地位。

本报告调查了全球抗TIGIT 抗体市场，并提供了市场概述、临床试验趋势、按适应症划分的临床管道趋势、患者细分和不同的临床管道趋势，以及进入该领域的公司的竞争格局市场.等等。

内容

第一章抗TIGIT抗体简介

第 2 章抗 TIGIT 抗体的作用（按适应症）

• 癌症
• 病毒感染
• 自身免疫性疾病

第 3 章 PD1 或 PDL1 抑制 TIGIT

第4章全球抗TIGIT抗体临床试验概述

• 按公司
• 按国家/地区
• 按指示
• 按患者细分
• 爱别

第 5 章按公司、适应症和阶段划分的全球抗 TIGIT 抗体临床管道

• 调查
• 临床前
• 第一阶段
• 第一/二期
• 第二阶段
• 第三阶段

第6章全球抗TIGIT抗体市场动态

第7章全球抗TIGIT抗体市场未来展望

第8章竞争态势

• Akeso Biopharma
• BeiGene
• Bio-Thera Solutions
• Biotheus
• Compugen
• FutureGen Biopharmaceutical
• Merck Sharp & Dohme
• Nanjing Sanhome Pharmaceutical
• OriCell Therapeutics
• Phio Pharmaceuticals
• Roche
• Shanghai Henlius Biotech
• Shanghai Junshi Biosciences
• Simcere Pharmaceutical Group
• Tasrif Pharmaceutical

“Anti TIGIT Antibody Market Opportunity & Clinical Trials Insight 2024 ” Report Highlights:

• Clinical Insight On Anti TIGIT Antibodies Clinical Trials Insight By Phase, Company, Country, Indication
• Anti TIGIT Antibodies In Clinical Trials : > 40
• Role of TIGIT Inhibitors by Indication
• Global Anti TIGIT Antibodies Market Dynamics
• Anti TIGIT Antibodies Market Future Outlook
• Key Companies Profile Involved in Development Of Anti TIGIT Antibodies

TIGIT is one of the most recent immune checkpoint inhibitors to emerge as a target for drugs that work by modulating its activity in the body. Both antagonists and agonists have been developed against the TIGIT, with the former predominating, and are mostly used in human diseases spanning various types. TIGIT inhibitors appear to be following a similar trend to immune checkpoint inhibitors, which have been widely tested against various cancers, and several preclinical and clinical studies are now being conducted to assess whether these novel inhibitors can replicate the therapeutic success shown by their counterparts. Several of these TIGIT inhibitors are now close to receiving regulatory approval, which is regarded to be a major driver for the development of TIGIT-targeting drugs.

Immune checkpoint proteins have gotten a lot of interest in the last few decades or so because of their potential as therapeutic targets. Checkpoint proteins such as TIGIT play a vital role in immune system control, and their activation and repression can have both beneficial and fatal consequences on the body depending on the disease indication. In recent years, researchers have found new immunological checkpoint proteins, including TIGIT, which was discovered a little more than a decade ago. The protein has three ligands: CD155, CD112, and CD113, which are all members of the nectin and NECL molecular families.

TIGIT has been found to downregulate the activity of T cells and NK cells, both of which are required for cancer cell elimination, acting as a hindrance to many aspects of the cancer immunity cycle. TIGIT blocking has been shown in preclinical tests to protect against a variety of solid and hematological malignancies. The similar thing has been observed in viral and bacterial infections, when immune system activation is essential for immune-mediated clearance of infected cells, which is hampered by TIGIT activation.

Several monoclonal and bispecific antibodies like AZD2936, PM1009, Domvanalimab and PM1021 have been produced to suppress the inhibitory activity of human TIGIT. TIGIT blocking is being studied in clinical studies as a monotherapy or in conjunction with anti-PD-1/PD-L1 monoclonal antibodies for the treatment of patients with advanced solid tumors.

TIGIT, on the other hand, has been linked to disease activity according to research on autoimmune diseases. A team of scientists announced the development of anti-mouse-TIGIT agonistic monoclonal antibody. The agonistic TIGIT antibody was utilized in mice models of experimental autoimmune encephalomyelitis, where it was claimed to improve disease symptoms by blocking T cell activation by acting on two different types of cells with differing effects. As a result, TIGIT-agnostic antibodies have the ability to reduce T cell imbalance in autoimmune disorders and are predicted to be especially effective in the treatment of autoimmune diseases.

There are currently no TIGIT antibodies with agonistic characteristics in clinical trials for the treatment of autoimmune disorders. Similarly, no antagonistic antibodies have entered clinical trials for the treatment of viral and bacterial infections, making both of these fields worthwhile to investigate given their enormous future potential.

A number of major global pharmaceutical companies, including Bristol-Myers Squibb, Roche, AstraZeneca, Biotheus, Arcus Biosciences, BeiGene, Akeso, and Compugen, are developing TIGIT-targeting drugs. To get their candidates through clinical trials, these companies have partnered with universities and health institutions such as Yale University, the University of Pittsburgh, and the MD Anderson Cancer Center. Some of these candidates are now in the final stages of clinical studies and show promise for regulatory approval.

Currently, the future market for TIGIT-targeting pharmaceuticals appears to be promising. Furthermore, with indications other than cancer showing promise for treatment with TIGIT agonists and antagonists, the breadth of anti-TIGIT drugs shows promise for disease expansion. The first TIGIT protein-targeting drug is expected to hit the market within the next 2-3 years, which will spark a rush of drug research, development, and commercialization deals, increased investment, and the development of technology platforms to allow the development of optimized anti-TIGIT drugs. Furthermore, as AI and nanotechnology join the drug discovery, development, and delivery processes, companies with AI and nanotechnology foundations are projected to become increasingly visible and significant in the TIGIT drugs industry.

Table of Contents

1. Introduction to Anti TIGIT Antibody

• 1.1. Overview
• 1.2. Mechanism of Anti TIGIT Antibodies
• 1.3. Clinical Approaches to Target TIGIT

2. Role of Anti TIGIT Antibody by Indication

• 2.1. Cancer
• 2.2. Viral Infections
• 2.3. Autoimmune Disorders

3. TIGIT Co Inhibition with PD1 or PDL1

4. Global Anti TIGIT Antibodies Clinical Trials Overview

• 4.1. By Company
• 4.2. By Country
• 4.3. By Indication
• 4.4. By Patient Segment
• 4.5. By Phase

5. Global Anti TIGIT Antibodies Clinical Pipeline By Company, Indication & Phase

• 5.1. Research
• 5.2. Preclinical
• 5.3. Phase-I
• 5.4. Phase-I/II
• 5.5. Phase-II
• 5.6. Phase-III

6. Global Anti TIGIT Antibodies Market Dynamics

• 6.1. Market Drivers
• 6.2. Commercialization Challenges

7. Global Anti TIGIT Antibodies Market Future Outlook

8. Competitive Landscape

• 8.1. Akeso Biopharma
• 8.2. BeiGene
• 8.3. Bio-Thera Solutions
• 8.4. Biotheus
• 8.5. Compugen
• 8.6. FutureGen Biopharmaceutical
• 8.7. Merck Sharp & Dohme
• 8.8. Nanjing Sanhome Pharmaceutical
• 8.9. OriCell Therapeutics
• 8.10. Phio Pharmaceuticals
• 8.11. Roche
• 8.12. Shanghai Henlius Biotech
• 8.13. Shanghai Junshi Biosciences
• 8.14. Simcere Pharmaceutical Group
• 8.15. Tasrif Pharmaceutical

List of Figures

• Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
• Figure 1-2: TIGIT Inhibitor - Proposed Mechanism of Action
• Figure 1-3: TIGIT Inhibitor - Mechanism of Action
• Figure 1-4: Binding Efficacy of Monoclonal Antibody
• Figure 1-5: Binding Efficacy of Bispecific Antibodies
• Figure 1-6: Advantages of Small Molecule Drugs over Therapeutic Antibodies
• Figure 2-1: Enhanced Anti-Tumor Effects of Dual TIGIT & PD-1 Blockade
• Figure 2-2: Blockade of TIGIT on Tregs Reduces Their Immunosuppressive Functions
• Figure 2-3: Blockade of TIGIT on NK Cells Augments Anti-Tumor Immunity
• Figure 2-4: Hypothetical Outcomes of Using TIGIT Blockade for HIV-1 Therapy
• Figure 2-5: TIGIT Associated Autoimmune Disorders
• Figure 4-1: Global - Anti TIGIT Antibodies Clinical Trials by Company (Number of Drugs), 2023 - 2024
• Figure 4-2: Global - Anti TIGIT Antibodies Clinical Trials by Country (Number of Drugs), 2023 - 2024
• Figure 4-3: Global - Anti TIGIT Antibodies Clinical Trials by Indication (Number of Drugs), 2023 - 2024
• Figure 4-4: Global - Anti TIGIT Antibodies Clinical Trials by Patient Segment (Number of Drugs), 2023 - 2024
• Figure 4-5: Global - Anti TIGIT Antibodies Clinical Trials by Phase (Number of Drugs), 2023 - 2024
• Figure 6-1: Global - Cancer Incidences & Deaths (Million), 2020 & 2025
• Figure 6-2: TIGIT Inhibitor Market Drivers
• Figure 6-3: Stages of Drug Development